RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

mRNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman Cut Its Rating on MRNA Earlier this month, Moderna reduced its 2025 ...

Scientists Katalin Kariko and Drew Weissmann have been awarded the 2023 Medicine Nobel Prize for their development of the mRNA technology for the production of Covid-19 vaccines, it was announced ...

mRNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by the U.S. government’s Department of Health and Human Services (HHS ...

Considering that PD-1/L1 are some of the most lucrative drug treatments across the industry, this could be a major coup for any mRNA developer that manages to successfully co-develop such a treatment.

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

US vaccines developer Moderna today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine ...

SAN DIEGO - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a $796 million market cap company known for supplying life science reagents and services, has announced the acquisition of intellectual property ...

They could also offer a more potent option to conventional flu shots, according to mRNA vaccine developers. Current flu vaccines generally offer only around 40% to 60% protective efficacy ...

We're learning more about a massive artificial intelligence infrastructure bill announced Tuesday by President Donald Trump.

RNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by ...